The concise guide to pharmacology....pdf (1.77 MB)
The concise guide to pharmacology 2021/22: enzymes
journal contribution
posted on 2023-11-17, 15:23 authored by Stephen PH Alexander, Stephanie AnnettStephanie Annett, Tracy RobsonTracy Robson, Szu Shen WongThe Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.15542. Enzymes are one of the six major pharmacological targets into which the Guide is divided, with the others being: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid-2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC-IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.
Funding
Case Feasibility Study for FKBPL based therapeutics in obesity and inflammatory related disorders | Funder: Enterprise Ireland | Grant ID: CF-2021-1810-Y
Charlemont Grant | Funder: Royal Irish Academy / RIA | Grant ID: RIA Charlemont Grants 201978
Evaluation of the functional effects FKBPL mutation, rs28732176, and implications for psoriasis | Funder: National Psoriasis Foundation | Grant ID: SA-IS-NPF-2022
Susan Komen Challenge 2019: Stress steroids and obesity; implications for breast cancer metastasis | Funder: Susan G Komen | Grant ID: RCSI-SGK-2019
Targeting obesity induced metastasis though FKBPL-based therapeutics | Funder: Irish Research Council
The Dramatic Effects of FKBPL on Adiposity via Gene Therapy (DEFLATE) | Funder: Higher Education Authority | Grant ID: SA-HEANS-2022
Uncovering the role of FKBPL in psoriasis | Funder: National Psoriasis Foundation | Grant ID: 852214
History
Comments
The original article is available at https://bpspubs.onlinelibrary.wiley.com/Published Citation
Alexander SPH. et al. The concise guide to pharmacology 2021/22: Enzymes. Br J Pharmacol. 2021;178 Suppl 1:S313-S411.Publication Date
16 September 2021External DOI
PubMed ID
34529828Department/Unit
- School of Pharmacy and Biomolecular Sciences
Research Area
- Immunity, Infection and Inflammation
- Endocrinology
- Cancer
Publisher
WileyVersion
- Published Version (Version of Record)